Skip to main content
SpringerLink
Log in

GlaxoSmithKline has priced Tykerb [lapatinib], its breast cancer agent, at a discount

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. GSK Tykerb priced at discount to Herceptin in metastatic breast cancer. FDC Reports - Pink Sheet - Prescription Pharmaceuticals and Biotechnology 69: 12, No. 2, 19 Mar 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

GlaxoSmithKline has priced Tykerb [lapatinib], its breast cancer agent, at a discount. Pharmacoecon. Outcomes News 526, 11 (2007). https://doi.org/10.2165/00151234-200705260-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705260-00027

Keywords

Search

Navigation